Physiologically based pharmacokinetic-pharmacodynamic modeling to predict concentrations and actions of sodium-dependent glucose transporter 2 inhibitor canagliflozin in human intestines and renal tubules.
about
Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus.Canagliflozin reduces plasma uremic toxins and alters the intestinal microbiota composition in a chronic kidney disease mouse model.Development of a Dynamic Physiologically Based Mechanistic Kidney Model to Predict Renal Clearance
P2860
Physiologically based pharmacokinetic-pharmacodynamic modeling to predict concentrations and actions of sodium-dependent glucose transporter 2 inhibitor canagliflozin in human intestines and renal tubules.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Physiologically based pharmaco ...... intestines and renal tubules.
@en
type
label
Physiologically based pharmaco ...... intestines and renal tubules.
@en
prefLabel
Physiologically based pharmaco ...... intestines and renal tubules.
@en
P2093
P2860
P356
P1476
Physiologically based pharmaco ...... n intestines and renal tubules
@en
P2093
Kazumi Mori
Makiko Shimizu
Ryuta Saito
Yoshinobu Nakamaru
P2860
P304
P356
10.1002/BDD.2040
P577
2016-09-29T00:00:00Z